Latest / Business Strategy Talks with Fexingo: Competitive Advantage, Market Positioning, and Growth Planning
How Novo Nordisk Built a Moat in Obesity Drugs
In this episode, Lucas and Luna explore how Novo Nordisk turned a diabetes drug into a blockbuster obesity treatment, building a decades-long moat that competitors like Eli Lilly are only now beginning to challenge. They trace the company's strategic bet on GLP-1 science in the 1990s, the manufacturing investments that created a supply advantage, and the intellectual property wall protecting semaglutide until the early 2030s. Specific numbers include the compound annual growth rate of Wegovy sales and the capacity expansion at Novo's Kalundborg facility. Lucas shares a clinical…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.